NASDAQ:MNOV

MediciNova Q1 2025 Earnings Results & Report

MediciNova logo
$1.31 +0.04 (+3.15%)
Closing price 04:00 PM Eastern
Extended Trading
$1.31 0.00 (0.00%)
As of 05:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MediciNova beat analyst earnings expectations in its Q1 2025 results, released May 13, 2025. The company reported EPS of -$0.06 versus the -$0.14 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

MediciNova EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

MediciNova Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

MediciNova Q1 2025 Earnings FAQ

MediciNova (NASDAQ:MNOV) reported earnings of -$0.06 per share for Q1 2025, beating the consensus estimate of -$0.14. The report was announced on Tuesday, May 13, 2025.

MediciNova Earnings Headlines

MediciNova FY2026 Earnings Forecast Boosted by HC Wainwright
Medicinova Inc
This is likely to EXPLODE
Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution risk, is warning of a looming $3 trillion threat in today's financial system. He says the same ratings agency practices that preceded the 2008 crisis are repeating themselves, while regulators stay quiet about the risks.tc pixel
MediciNova to Participate in the Maxim Growth Summit
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
See More MediciNova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email.

About MediciNova

MediciNova (NASDAQ:MNOV) is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries.

Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders. MediciNova is also developing MN-001 (tipelukast) for potential uses in metabolic and fibrotic diseases. These candidates are investigational and have not been approved as medicines.

MediciNova was founded in 2000. Yuichi Iwaki, M.D., Ph.D., is the company’s founder, president and chief executive officer.

View MediciNova Profile